In the latest session, Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) closed at $18.70 down -5.46% from its previous closing price of $19.78. In other words, the price has decreased by -$1.08 from its previous closing price. On the day, 998586 shares were traded. AMLX stock price reached its highest trading level at $19.76 during the session, while it also had its lowest trading level at $18.56.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Ratios:
For a deeper understanding of Amylyx Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.30 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on July 24, 2023, Upgraded its rating to Buy and sets its target price to $49 from $45 previously.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 15 when Mazzariello Gina sold 6,164 shares for $20.88 per share. The transaction valued at 128,686 led to the insider holds 49,083 shares of the business.
FRATES JAMES M sold 32,500 shares of AMLX for $875,451 on May 16. The Chief Financial Officer now owns 55,676 shares after completing the transaction at $26.94 per share. On May 15, another insider, Yeramian Patrick D, who serves as the Chief Medical Officer of the company, sold 11,965 shares for $29.03 each. As a result, the insider received 347,358 and left with 208,417 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 1.26B and an Enterprise Value of 907.97M. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.51 while its Price-to-Book (P/B) ratio in mrq is 3.25. Its current Enterprise Value per Revenue stands at 4.73 whereas that against EBITDA is -11.31.
Stock Price History:
Over the past 52 weeks, AMLX has reached a high of $41.93, while it has fallen to a 52-week low of $19.36. The 50-Day Moving Average of the stock is 21.64, while the 200-Day Moving Average is calculated to be 28.98.
Shares Statistics:
For the past three months, AMLX has traded an average of 1.16M shares per day and 992.05k over the past ten days. A total of 67.23M shares are outstanding, with a floating share count of 51.17M. Insiders hold about 22.79% of the company’s shares, while institutions hold 65.70% stake in the company. Shares short for AMLX as of Aug 30, 2023 were 8.58M with a Short Ratio of 8.58M, compared to 8.49M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.73% and a Short% of Float of 16.99%.
Earnings Estimates
There are 4 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.45 for the current quarter, with a high estimate of $0.56 and a low estimate of $0.37, while EPS last year was -$0.92. The consensus estimate for the next quarter is $0.54, with high estimates of $0.62 and low estimates of $0.43.
Analysts are recommending an EPS of between $1.42 and $0.94 for the fiscal current year, implying an average EPS of $1.26. EPS for the following year is $3.77, with 3 analysts recommending between $4.2 and $2.97.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $116.12M this quarter.It ranges from a high estimate of $122.84M to a low estimate of $110.9M. As of the current estimate, Amylyx Pharmaceuticals Inc.’s year-ago sales were $345k, an estimated increase of 33,558.00% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $129.3M, an increase of 490.80% less than the figure of $33,558.00% in the same quarter last year. There is a high estimate of $137.87M for the next quarter, whereas the lowest estimate is $123.2M.
A total of 5 analysts have provided revenue estimates for AMLX’s current fiscal year. The highest revenue estimate was $425.76M, while the lowest revenue estimate was $403.8M, resulting in an average revenue estimate of $414.94M. In the same quarter a year ago, actual revenue was $22.23M, up 1,766.60% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $639.09M in the next fiscal year. The high estimate is $702.8M and the low estimate is $524M. The average revenue growth estimate for next year is up 54.00% from the average revenue estimate for this year.